US 12,186,386 B2
Recombinant RSV with silent mutations, vaccines, and methods related thereto
Martin L. Moore, Decatur, GA (US); Jia Meng, Atlanta, GA (US); Anne Hotard, Atlanta, GA (US); Elizabeth Littauer, Decatur, GA (US); and Christopher Stobart, Decatur, GA (US)
Assigned to Emory University and Children's Healthcare of Atlanta, Inc., Atlanta, GA (US)
Filed by Emory University, Atlanta, GA (US); and Children's Healthcare of Atlanta, Inc., Atlanta, GA (US)
Filed on Oct. 14, 2022, as Appl. No. 18/046,743.
Application 16/263,915 is a division of application No. 14/775,671, granted, now 10,232,032, issued on Mar. 19, 2019, previously published as PCT/US2014/027447, filed on Mar. 14, 2014.
Application 18/046,743 is a continuation of application No. 17/025,568, filed on Sep. 18, 2020, granted, now 11,471,524.
Application 17/025,568 is a continuation of application No. 16/263,915, filed on Jan. 31, 2019, granted, now 10,792,356, issued on Oct. 6, 2020.
Claims priority of provisional application 61/890,500, filed on Oct. 14, 2013.
Claims priority of provisional application 61/781,228, filed on Mar. 14, 2013.
Prior Publication US 2023/0302115 A1, Sep. 28, 2023
Int. Cl. A61K 39/155 (2006.01); A61K 39/12 (2006.01); A61K 45/06 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/155 (2013.01) [A61K 39/12 (2013.01); A61K 45/06 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/55 (2013.01); A61K 2039/58 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18562 (2013.01); C12N 2800/22 (2013.01)] 6 Claims
 
1. An isolated recombinant nucleic acid comprising a NS1 gene of the RSV genome, wherein the NS1 gene has at least 90% sequence identity to SEQ ID NO: 6; wherein the isolated nucleic acid encodes a NS1 protein having sequence as set forth in SEQ ID NO: 5.